Expert Review of Pharmacoeconomics & Outcomes Research

[1]  J. Grimshaw,et al.  From best evidence to best practice: effective implementation of change in patients' care , 2003, The Lancet.

[2]  Pommerville Pj,et al.  GnRH antagonists in the treatment of advanced prostate cancer. , 2010 .

[3]  S. Feigenberg,et al.  Long‐term hormone therapy and radiation is cost‐effective for patients with locally advanced prostate carcinoma , 2006, Cancer.

[4]  Jesse Green,et al.  The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. , 2004, Journal of hepatology.

[5]  M. Miquel,et al.  De novo depression and anxiety disorders and influence on adherence during peginterferon‐alpha‐2a and ribavirin treatment in patients with hepatitis C , 2007, Alimentary pharmacology & therapeutics.

[6]  Jing Jing Li,et al.  Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. , 2009, JAMA.

[7]  L. Pradelli,et al.  Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  J. Beck,et al.  Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10). , 2005, International journal of radiation oncology, biology, physics.

[9]  Michael Drummond,et al.  Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Gerber,et al.  Health‐related quality of life in patients with non‐alcoholic fatty liver disease , 2007, Alimentary pharmacology & therapeutics.

[11]  S. Ramsey,et al.  The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. , 2005, The Journal of urology.

[12]  P. Dunscombe,et al.  A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer. , 2003, Urologic oncology.

[13]  K. Stein,et al.  Cost‐effectiveness analysis of degarelix for advanced hormone‐dependent prostate cancer , 2012, BJU international.

[14]  N. Brereton,et al.  PCN100 A Cost–Utility Analysis of Degarelix in the Treatment of Advanced Hormone-Dependent Prostate Cancer in Scotland , 2011 .

[15]  E. Schiff,et al.  Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. , 2004, Gastroenterology.

[16]  E. Crawford,et al.  Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. , 2010, European urology.

[17]  S. Ramsey,et al.  Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? , 2005, Urology.

[18]  S. Bryan,et al.  How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach , 2007, Journal of health services research & policy.

[19]  H. Lepor,et al.  Androgen deprivation therapy in the treatment of advanced prostate cancer. , 2007, Reviews in urology.

[20]  D. Patrick,et al.  Patient-reported outcomes to support medical product labeling claims: FDA perspective. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[21]  M. Drummond,et al.  European perspective on the costs and cost-effectiveness of cancer therapies. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M C Weinstein,et al.  Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease. , 2001, International journal of technology assessment in health care.

[23]  E D Crawford,et al.  Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. , 1995, Urology.

[24]  B. McNeil,et al.  Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? , 2010, Urology.

[25]  J. Beaumont,et al.  Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[26]  H. Bonkovsky,et al.  Antiviral Response of HCV Genotype 1 to Consensus Interferon and Ribavirin Versus Pegylated Interferon and Ribavirin , 2007, Digestive Diseases and Sciences.

[27]  A. Konski.  Cost–effectiveness of intensity-modulated radiation therapy , 2005, Expert review of pharmacoeconomics & outcomes research.

[28]  Z. Younossi,et al.  Depression, anemia and health-related quality of life in chronic hepatitis C. , 2006, Journal of hepatology.

[29]  Jing Jing Li,et al.  The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004 , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[30]  Creating models that meet decision makers' needs: a US payer perspective. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[31]  Adalsteinn D. Brown,et al.  Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. , 2000, Journal of the National Cancer Institute.

[32]  T. Purmonen.  Cost–effectiveness of sunitinib in metastatic renal cell carcinoma , 2011, Expert review of pharmacoeconomics & outcomes research.

[33]  P. Saylor,et al.  Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[34]  Karl Claxton,et al.  Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion. , 2006, Health economics.

[35]  O. Weiland,et al.  Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C , 2006, Scandinavian journal of gastroenterology.

[36]  C. Roehrborn,et al.  The economic burden of prostate cancer , 2011, BJU international.

[37]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.

[38]  S. Grosse.  Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold , 2008, Expert review of pharmacoeconomics & outcomes research.

[39]  Karl Claxton,et al.  Value of information and value of implementation: application of an analytic framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[40]  E. Mackenzie,et al.  Early Packed Red Blood Cell Transfusion and Acute Respiratory Distress Syndrome after Trauma , 2009, Anesthesiology.

[41]  T. Gorlia,et al.  Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. , 2002, Health economics.